Omeros (OMER) Total Non-Current Liabilities (2021 - 2026)

Omeros' (OMER) quarterly Total Non-Current Liabilities came in at $265.5 million in Q1 2026, down 40.24% year-on-year from $444.2 million in Q1 2025, and down 39.82% quarter-over-quarter from $441.2 million in Q4 2025.

Omeros (OMER) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Omeros has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $265.5 million for Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $265.5 million, down 40.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $265.5 million (down 40.24% YoY), and the FY2025 annual result was $441.2 million, down 3.08% from the prior year.
  • Total Non-Current Liabilities came in at $265.5 million for Q1 2026 at Omeros, down from $441.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $507.0 million in Q3 2023 to a low of $251.2 million in Q2 2025.
  • The 5-year median for Total Non-Current Liabilities is $455.2 million (2024), against an average of $425.8 million.
  • Across the five-year window, Total Non-Current Liabilities soared 35.22% in 2023 and slumped 47.54% in 2025, its largest moves.
  • Omeros' Total Non-Current Liabilities stood at $504.8 million in 2022, then decreased by 20.54% to $401.2 million in 2023, then gained by 13.47% to $455.2 million in 2024, then declined by 3.08% to $441.2 million in 2025, then plunged by 39.82% to $265.5 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $265.5 million (Q1 2026), $441.2 million (Q4 2025), and $253.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 42,980.09
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 11.03 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 95.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 644,700.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.96 Bn 91.96 Bn - 64.76 Mn
10 Omeros 737.87 Mn 602.55 Mn 9.31 Mn 265.48 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 265.48 Mn
Dec 31, 2025 441.16 Mn
Sep 30, 2025 253.66 Mn
Jun 30, 2025 251.17 Mn
Mar 31, 2025 444.21 Mn
Dec 31, 2024 455.19 Mn
Sep 30, 2024 464.41 Mn
Jun 30, 2024 478.82 Mn
Mar 31, 2024 506.73 Mn
Dec 31, 2023 401.16 Mn
Sep 30, 2023 507.02 Mn
Jun 30, 2023 506.42 Mn
Mar 31, 2023 504.74 Mn
Dec 31, 2022 504.84 Mn
Sep 30, 2022 502.87 Mn
Jun 30, 2022 377.38 Mn
Mar 31, 2022 373.27 Mn
Dec 31, 2021 394.37 Mn